

SILSOL® SILICA-BASED DRUG DELIVERY TECHNOLOGY

The Bioavailability Challenge

Grace's SILSOL® Silica-based Drug Delivery Technology was engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to help more effectively formulate a large class of poorly soluble but otherwise promising compounds.

SILSOL® Silica Drug Delivery Technology gives pharmaceutical developers a new drug delivery option for enhanced bioavailability of BCS2 (poorly soluble) compounds. BCS2 compounds account for 40 percent of the APIs on the market today, 70 to 80 percent of pharmaceuticals active in the pipeline and those that have been shelved due to solubility issues. In total, BCS2 compounds represent an estimated market opportunity of \$5 billion.

The Grace® Silica Advantage

Grace's silicas have been used in pharmaceutical formulations since the 1960's and we continue to innovate today. SILSOL® Silica Drug Delivery Technology combines our expertise in mesoporous silica gel, novel application methods, and patent pending technologies to accelerate the screening and development of solubility enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.

How Does It Work?

Grace's SILSOL® Silica Drug Delivery Technology can be used with both solvent impregnation and solvent-free techniques to create amorphous solid dispersions.

Grace's SILSOL® Silica Drug Delivery Technology Offers Five Major Benefits:

- **Enhanced Bioavailability** – through delivery of the amorphous form of drugs
- **Stability** – Amorphous solid dispersions prevent re-crystallization
- **Pharmacopoeia Acceptance** – GMP manufactured silica conforms to Global monographs
- **Scalability** – Grams to tons quantities under excipient GMP manufacture
- **FDA Compliance** – Material is listed on the FDA inactive ingredient database

Solvent Techniques	Solvent Free Techniques
Crystalline API, which is difficult for the body to absorb, is dissolved in a volatile solvent to create a solution of amorphous API.	Crystalline API, which is difficult for the body to absorb, is mixed with specifically engineered silica.
Grace's silica material is impregnated with the API-solvent solution.	The mixture is milled or compressed to introduce energy into the mixture.
The API is deposited into the silica's mesopores.	The energy creates an amorphous form of the API and breaks down the silica particle so more of the surface can interact with the API.
The solvent is then evaporated from the particles.	Equilibrium is created to form a new particle that suppresses the re-crystallization of the API.
Silica pores suppress the tendency of the API molecule to re-crystallize.	The amorphous API is released from the particles and becomes available in the gastrointestinal system.
The amorphous API is released from the pores and becomes available in the gastrointestinal system.	

GRACE

Talent | Technology | Trust™



Trust Grace

Grace has been a respected provider of silica materials for the pharmaceutical and other industries for more than a century. Laboratory experiments and studies—reported in over 300 scientific publications—have concluded that silica could support bioavailability of difficult-to-absorb APIs.

Grace's SILSOL® Silica-based Drug Delivery Technology offers a potentially simple solution to a complex challenge, enabling shelved candidates to become viable drugs for patients.



Grace's Silica Engineering

Through molecular engineering, Grace can modify the pore size and surface characteristics of silica to accommodate various API molecules. The net result is enhanced bioavailability with stability.

The SILSOL® Silica Technology Advantage—Simplicity

Compared to other bioavailability enhancing techniques such as particle size reduction, complexation, lipid-based systems and polymer-based solid dispersions, Grace's SILSOL® Silica Technology introduces techniques that are often easier to screen, less complex to make, and require less time when scaling up.

- Suitable for NCE, life cycle management, reformulations, and repositioning
- Applicable to a broad range of compounds (including all BCS2 poorly solubles)
- Easy and cost effective introduction into established manufacturing units
- Generate stable formulations



Grace Corporate Headquarters

W. R. Grace & Co.-Conn
7500 Grace Drive
Columbia, MD 21044 USA
Tel: +1.410.531.4000

Regional Locations

Latin America
São Paulo, Brasil
Tel: +55.11.4197.7540

Asia/Pacific
Shanghai, China
Tel: +86.21.3325.8288

Europe
Worms, Germany
Tel: +49.6241.40300

grace.com

The information presented herein is derived from our testing and experience. It is offered for your consideration and verification. Since operating conditions vary significantly, and are not under our control, we disclaim all warranties on the results that may be obtained from the use of our products. W. R. Grace & Co.-Conn. and its subsidiaries can not be held responsible for any damage or injury occurring as a result of improper installation or use of its products. Grace reserves the right to change prices and/or specifications without prior notification. GRACE® and SILSOL® are trademarks, registered in the United States and/or other countries, of W. R. Grace & Co.-Conn. TALENT TECHNOLOGY TRUST™ is a trademark of W. R. Grace & Co.-Conn. This trademark list has been compiled using available published information as of the publication date of this brochure and may not accurately reflect current trademark ownership or status. © Copyright 2018 W. R. Grace & Co.-Conn. All rights reserved. DOC021

GRACE
Talent | Technology | Trust™